Many of the hot new drug candidates in the U.S. were developed by Chinese companies.
Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong ...
Anthropic acquired a single-employee biotech start-up to demonstrate how AI can streamline drug development, with plans to advance treatments into human clinical trials by 2028.
Regulators issued the hold for Bright Minds' BMB-101 after identifying toxicity issues in preclinical mouse models.
A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech's shares, while a late-stage lung cancer miss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results